Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06446739
Other study ID # 00140224
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date July 2025

Study information

Verified date June 2024
Source University of Alberta
Contact Sean M Bagshaw, MD
Phone 780-248-1256
Email bagshaw@ualberta.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An estimated 10-15% of critically ill patients with acute kidney failure in the intensive care unit receive acute dialysis therapy. The majority of these patients initially receive continuous for of dialysis therapy call continuous renal replacement therapy (CRRT). Prior studies have suggested that higher CRRT dose-intensity improved health outcomes for these patients; however, this was not found in high-quality clinical trials. These more recent trials suggested a lower range of dose-intensity compared with the higher range as the new standard of care. This was incorporated into guidelines. To date, no clinical trials have evaluated this lower range and specifically, it is plausible that an even lower dose-intensity of CRRT may be well tolerated, safe, associated with similar outcomes and be more cost-effective. This is the objective of the WISDOM trial, to compare the guideline standard with lower dose-intensity among patients who are started on CRRT in the intensive care unit.


Description:

Purpose: To primarily determine whether a lower CRRT dose-intensity in critically ill patients with acute kidney injury (AKI) is non-inferior to standard CRRT dose-intensity and to secondarily determined whether lower CRRT dose intensity will shorten total CRRT duration and improve kidney recovery compared with standard CRRT dose-intensity. This pilot trial will specifically evaluate the feasibility and tolerability of lower versus standard CRRT dose-intensity. Hypothesis: The primary hypothesis of the WISDOM trial is that lower CRRT dose-intensity is non-inferior to current standard guideline-directed CRRT dose-intensity for critically ill patients with AKI with respect to duration of CRRT and successful liberation from RRT and kidney recovery. The secondary hypothesis of the WISDOM trial is that lower dose-intensity is superior to current standard guideline-directed CRRT dose-intensity for critically ill patients with AKI with respect to duration of CRRT and successful liberation from RRT and kidney recovery. Justification: No randomized controlled trial (RCT) to date has specifically evaluated the lower dose-intensity threshold for critically ill patients receiving CRRT. Specifically, there has been no specific evidence or guidance on the minimum dose-intensity targets for patients receiving CRRT. This is important for several reasons. First, CRRT is an invasive, resource intensive and expensive therapy. As such, there should be a concerted effort to minimize time on RRT and facilitate early recovery and weaning. Second, abundant evidence derived from secondary analyses have suggested that higher CRRT dose-intensity can propagate oliguria, prolong CRRT therapy and delay kidney recovery. This would imply that lower dose-intensity may facilitate kidney recovery and earlier weaning from CRRT. Third, there may be added implications of higher dose-intensity, including prolongation of non-renal organ support, such as delay in weaning from invasive mechanical ventilation. Fourth, evidence derived from observational registries show that lower CRRT dose-intensity, in the range proposed in this trial, provides comparable efficacy in azotemic, metabolic and acid-base homeostasis with similar outcomes. Observational data have suggested a prescribed CRRT dose-intensity of 15 mL/kg/hr may be sufficient for metabolic and azotemic control and is not associated with worse outcomes compared with guideline directed dose-intensity. This is lower quality evidence, however, implies that lower dose-intensity may be acceptable and safe. Fifth, it is plausible that following a short period of metabolic stabilization with CRRT, the minimum recommended CRRT dose-intensity of 20-25 mL/kg/hr may be excessive and have unmeasurable harm (e.g., excessive clearance of electrolytes, micronutrients, and medications [antimicrobials]). Finally, the prescription of a lower CRRT dose-intensity may have meaningful impact on reducing bedside nursing workload (e.g., fewer replacement solution bag changes) and reducing costs attributable to CRRT (e.g., lower effluent rates will reduce total replacement solution utilized). While this proposal outlines a pilot feasibility trial, it is aimed at performing a larger rigorous RCT that will generate generalizable and high-quality evidence to impact clinical practice. The findings of the main phase of the WISDOM trial will provide clearer evidence to guide the prescription of a minimal dose-intensity for patients receiving CRRT. While this may be an effluent dose of 20-25 mL/kg/hr, it is entirely plausible that this will be a lower dose-intensity. Objectives: The overall WISDOM trial program will address whether a lower CRRT dose-intensity in critically ill patients with AKI is non-inferior to standard CRRT dose-intensity and will secondarily address whether lower CRRT dose intensity will shorten total CRRT duration and improve kidney recovery compared with standard CRRT dose-intensity.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date July 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - age > 18 years - clinical team decision to initiate CRRT associated with AKI - within 18 hours of commencement of CRRT - expected to receive CRRT for a duration of = 48 hours - able to provide informed consent or have an authorized representative provide consent after being informed on the details and risks of the trial unless a waiver of consent process is approved by local Research Ethics Board (REB). Exclusion Criteria: - absolute indication for higher dose-intensity CRRT - end-stage kidney disease receiving maintenance dialysis - inability to comply with the requirements of the study protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Continuous Renal Replacement Therapy (CRRT)
Continuous Renal Replacement Therapy (CRRT) is a continuous form of acute renal replacement (hemofiltration/dialysis) therapy provided to critically ill patients with multi-organ dysfunction receiving life support in the intensive care unit (ICU).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Outcome

Type Measure Description Time frame Safety issue
Other Daily bicarbonate while receiving CRRT, an average of 1 month. Physiological and biochemical outcomes. Through study completion, at 90-days.
Other Daily serum phosphate while receiving CRRT, an average of 1 month Physiological and biochemical outcomes. Through study completion, at 90-days.
Other Daily serum urea while receiving CRRT, an average of 1 month Physiological and biochemical outcomes. Through study completion, at 90-days.
Other The total treatment time per day while receiving CRRT following randomization. Process of care measures. Through study completion, at 90-days.
Other The number of planned and unplanned hemofilter/circuit replacements while receiving CRRT following randomization. Process of care measures. Through study completion, at 90-days.
Other The lowest and higher CRRT dose-intensity delivered for any given hour following randomization. Process of care measures. While receiving CRRT, an average of 1 month.
Other The proportion of hours of CRRT when the dose-intensity is in the target range following randomization. Process of care measures. Through study completion, at 90-days.
Other Occurrence of adverse and serious adverse events. Safety measures. Through study completion, at 90-days.
Other Occurrence of adverse events and serious adverse events leading to discontinuation of the trial intervention. Safety measures. Through study completion, at 90-days.
Other RRT-free days at 90-days. Clinical Outcomes. Through study completion, at 90-days.
Primary Difference in delivered CRRT dose-intensity This pilot trial will target detection of a minimum difference of 10 mL/kg/hr in delivered dose-intensity. Through study completion, an average of 1 month.
Secondary Feasibility - consent rate Consent rate for participation by patient or surrogate decision-maker (SDM). Through study completion, at 90-days.
Secondary Feasibility - time to enrollment Time from eligibility (e.g., starting RRT) to randomization. During active recruitment into the trial, approximately 1 year.
Secondary Feasibility - adherence to prescribed CRRT dose-intensity Protocol adherence for allocated CRRT dose-intensity. Through study completion, at 90-days.
Secondary Feasibility - ascertainment to delivered CRRT process measures Ability to capture delivered CRRT dose-intensity measures. Through study completion, at 90-days.
Secondary Feasibility - outcome ascertainment Ability to capture patient and kidney endpoints at 90-days. Through study completion, at 90-days.
Secondary Feasibility - recruitment rate Ability to recruit 2 patients per site per month. During active recruitment into the trial, approximately 1 year.
See also
  Status Clinical Trial Phase
Recruiting NCT05538351 - A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03938038 - Guidance of Ultrasound in Intensive Care to Direct Euvolemia N/A
Recruiting NCT05805709 - A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial N/A
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Recruiting NCT05897840 - Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients N/A
Recruiting NCT04986137 - Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
Terminated NCT04293744 - Acute Kidney Injury After Cardiac Surgery N/A
Completed NCT04095143 - Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
Not yet recruiting NCT06026592 - Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Not yet recruiting NCT06064305 - Transcriptional and Proteomic Analysis of Acute Kidney Injury
Terminated NCT03438877 - Intensive Versus Regular Dosage For PD In AKI. N/A
Terminated NCT03305549 - Recovery After Dialysis-Requiring Acute Kidney Injury N/A
Completed NCT05990660 - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery N/A
Completed NCT04062994 - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Terminated NCT02860130 - Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) Phase 3
Completed NCT06000098 - Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
Not yet recruiting NCT05548725 - Relation Between Acute Kidney Injury and Mineral Bone Disease
Completed NCT02665377 - Prevention of Akute Kidney Injury, Hearttransplant, ANP Phase 3
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A